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Abstract
Approximately 25–30% of colorectal cancer (CRC) cases are expected to result from a
genetic predisposition, but in only 5–10% of these cases highly penetrant germline muta-
tions are found. The remaining CRC heritability is still unexplained, and may be caused by a
hitherto-undefined set of rare variants with a moderately penetrant risk. Here we aimed to
identify novel risk factors for early-onset CRC using whole-exome sequencing, which was
performed on a cohort of CRC individuals (n = 55) with a disease onset before 45 years of
age. We searched for genes that were recurrently affected by rare variants (minor allele fre-
quency0.001) with potentially damaging effects and, subsequently, re-sequenced the
candidate genes in a replication cohort of 174 early-onset or familial CRC individuals. Two
functionally relevant genes with low frequency variants with potentially damaging effects,
PTPN12 and LRP6, were found in at least three individuals. The protein tyrosine phospha-
tase PTP-PEST, encoded by PTPN12, is a regulator of cell motility and LRP6 is a compo-
nent of the WNT-FZD-LRP5-LRP6 complex that triggers WNT signaling. All variants in
LRP6 were identified in individuals with an extremely early-onset of the disease (30 years
of age), and two of the three variants showed increased WNT signaling activity in vitro. In
conclusion, we present PTPN12 and LRP6 as novel candidates contributing to the hetero-
geneous susceptibility to CRC.
Author Summary
Onset of colorectal cancer (CRC) at an early age in life is suggestive of a hereditary predis-
position. However, a large proportion of the heritability of early-onset CRC is still unex-
plained. We aimed to identify novel genes that may confer CRC susceptibility by whole-
exome sequencing of 55 individuals that were diagnosed with this disease before the age of
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45 years. To identify candidate causative variants, we applied a strategy in which we
searched for genes with multiple rare (minor allele frequency0.001) variants in cases but
not in controls with a potentially damaging effect, and with a functional link to (colorectal)
cancer development. Based on targeted re-sequencing and functional analyses we identi-
fied LRP6 and PTPN12 as novel candidate genes for CRC susceptibility. A validation of
these genes in larger independent case and control cohorts is needed to establish the pre-
cise role of these genes in the susceptibility to develop CRC.
Introduction
Colorectal cancer (CRC) is a heterogeneous disease with an estimated heritable component of
25–30%. About 5–10% of CRC cases are currently explained by germline mutations in genes
that predispose to Mendelian cancer syndromes, such as Lynch syndrome, Familial Adomatous
Polyposis, Peutz-Jeghers syndrome, Juvenile Polyposis syndrome,MUTYH-associated polypo-
sis, NTHL1-associated polyposis, and Polymerase Proofreading-associated Polyposis syn-
drome.[1–5] Typically, these CRC syndromes are marked by a strong family history, a high-
penetrance of the disease, and the development of multiple tumors at an early age.[1] An addi-
tional 10% of the heritability of CRC may be explained by a growing list of common, low pene-
trant risk factors.[5–7] In spite of this, a large part of the heritability of CRC still remains
unexplained and may well result from the presence of rare variants with a moderate risk.[8]
Moderately penetrant risk factors do not necessarily result in dominant traits, since their
phenotypic effects may rely on an interplay with other genetic and/or environmental factors.
[2] However, these genetic factors may play a role in individuals with an early-onset of the dis-
ease, one of the hallmarks of hereditary cancer.[9] In addition, unexplained early-onset CRC
cases differ from late-onset sporadic CRC cases based on their distinct clinical, molecular, and
pathological etiology.[10]
Here, we used whole-exome sequencing to identify novel moderately penetrant CRC risk
factors. Since we expect such factors to follow non-Mendelian inheritance patterns, we focused
specifically on individuals with an early onset of the disease, which frequently manifests in the
absence of a clear family history. We selected recurrent rare variants in genes with a low burden
of comparable variants in controls, and identified PTPN12 and LRP6 as novel candidate risk
factors for early-onset CRC.
Results
Whole-exome sequencing of early-onset CRC cases
To identify rare genetic variants involved in CRC susceptibility, we performed whole-exome
sequencing on germline DNA from 55 CRC cases, diagnosed at age 45 years or younger. The
average age at diagnosis was 35 years [range: 23–45] and 22 cases (40%) had a positive family
history for cancer (Table 1 and S1 Table). The average coverage per target region was 76x
[range: 46-127x] with on average 43,124 identified variants [range: 29,040–49,929] per exome
(detailed metrics per exome are listed in S2 Table). In total 2,381,720 variants were identified.
After quality assessment, common variants were excluded, which were defined as variants that
are present in our in-house database with 2,037 exomes from mostly Western-European ances-
try or the Exome variant server (EVS) with minor allele frequencies (MAF)>0.001.[11] Subse-
quently, we selected variants that result in protein truncation (i.e. frameshift or nonsense
mutations and variants at canonical splice sites) and missense substitutions at highly conserved
Novel CRC Susceptibility Genes
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positions (non-synonymous variants with a PhyloP score3; see Materials and Methods for a
detailed description). We identified on average 34 [range: 10–89] rare variants per sample,
including on average 5 [range: 1–10] protein truncating variants and 29 [range: 8–83] missense
variants. In total, 279 protein truncating and 1,584 missense variants were identified (S3
Table). These potentially pathogenic variants were subjected to a subsequent filtering strategy
to identify known and novel CRC predisposing gene variants (Fig 1).
Variants in (colorectal) cancer predisposing genes
Within the list of potentially pathogenic variants, we analyzed whether these variants were
present in any of the known CRC predisposing genes, i.e, mismatch repair (MMR) genes, APC,
POLD1, POLE, SMAD4, BMPR1A,MUTYH, NTHL1. In three individuals, variants in the
MMR genesMSH2,MSH6 (three variants) and PMS2 were identified (S4 Table), but based on
microsatellite instability or immunohistochemistry analyses none of these variants resulted in
MMR deficiency. Therefore, these variants were allocated to be of unknown significance.
Next, we focused on variants in genes known to predispose to other types of cancer or to
cause cancer syndromes when present in a biallelic state.[12,13] We identified eight variants in
six different genes (S5 Table). Two of these genes, BLM and ATM, were found to harbor rare
variants in two patients. BLM encodes a RECQL-DNA helicase and is involved in the recessive
Bloom syndrome, which predisposes to CRC. Although current literature on the risk of CRC
development in carriers of pathogenic BLM alleles is contradictory [14–16], we recently found
by targeted re-sequencing of a validation cohort that monoallelic pathogenic BLM variants
were enriched in these cases.[17] ATM is involved in double-strand break repair and mutations
in its encoding gene are associated with ataxia telangiectasia, another autosomal recessive dis-
order. Somatic nonsense mutations in ATM occur frequently in CRC, but monoallelic germline
Table 1. Clinical characteristics of the discovery and replication cohorts with mismatch-repair proficient colorectal cancer.
Characteristic Exome cohort (%) N = 55 Dutch replication cohort (%) N = 82 German replication cohort (%) N = 92
Average age of onset (SD) 35 (4) 40.4 (4.5) 37.7 (5.6)
Average age
25 yr 2 (4) 1 (1) 1 (1)
25–30 yr 8 (15) 2 (2) 12 (13)
31–35 yr 17 (31) 10 (12) 16 (17)
36–40 yr 26 (47) 21 (26) 27 (29)
40–45 yr 2 (4) 46 (56) 35 (38)
45–50 yr - 2 (2) 1 (1)
Family history for cancer
None 27 (49) 23 (28) 4 (4)
one ﬁrst degree relative 10 (18) 33 (40) 37 (3)
one second degree relative 10 (18) 13 (16) 20 (22)
one third degree relatives 2 (4) 1 (1) 1 (1)
Unknown 6 (11) 12 (15) 30 (33)
Tumor location
Right colon 8 (15) 7 (9) 15 (16)
Transverse colon 4 (7) 8 (10) 9 (10)
Left colon 13 (24) 13 (16) 25 (27)
Rectum 25 (46) 32 (39) 33 (36)
Unknown 6 (11) 19 (23) 10 (11)
doi:10.1371/journal.pgen.1005880.t001
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mutations have thus far only been shown to increase the risk for gastric, breast and pancreatic
cancers, and mostly when they result in truncated proteins.[18–20] Potentially pathogenic mis-
sense variants in ATM were also found twice in a cohort of 164 healthy individuals (Control
dataset 1; see Materials and Methods and below) and we, therefore, conclude that ATM is not
enriched in our cohort of CRC cases. The remaining four variants represent highly conserved
missense or protein truncating variants that occurred in four different genes: BRIP1, EGFR,
ERCC3 andWRN (S5 Table).
Identification of novel CRC susceptibility genes
To identify novel candidate CRC susceptibility genes, we first focused on genes with biallelic
mutations (recessive inheritance pattern). Therefore, we analysed our list of potentially patho-
genic variants for the presence of autosomal homozygous (95% variant reads) or compound
heterozygous variants and, subsequently, performed Sanger validation. We identified biallelic
variants in eight individuals, all affecting different genes (Fig 1, S6 Table). However, these
genes were either found to be be linked to other phenotypes, to contain many rare variants in
the general population, or to have a function that remains to be elucidated. Therefore, these
variants were excluded from further analysis.
Subsequently, we filtered our list of potentially pathogenic variants for genes with at least
two variants in unrelated individuals (see Materials and Methods for details). In total, we iden-
tified 445 rare potentially pathogenic variants in 196 recurrently affected genes. Some of these
genes contain many rare variants that occur in the general population and are, thus, unlikely to
provoke an increased risk for CRC. Therefore, we selected an exome sequencing data set from
healthy individuals (Control dataset 1; n = 164) that were subjected to the same procedure as
our CRC cohort and were found to be comparable based on genotyping accuracy and popula-
tion (S1 Fig; see Materials and Methods for a detailed description). This ‘Control dataset 1’ was
used to remove genes from our list that were not significantly enriched in the CRC cohort after
a χ2 goodness of fit test (S7 Table; Materials and Methods). The remaining variants, i.e., 347
variants in 150 genes, were subjected to a four-step prioritization as outlined below and
depicted in Fig 1.
First, we investigated whether genes were recurrently affected by rare protein truncating
variants. Only one gene, EMR3, was found to fulfill this criterion with two splice site mutations
(Table 2), each predicted to result in skipping of an exon. EMR3 belongs to the EGF-TM7 pro-
tein family of G-protein coupled receptors and is specifically expressed in granulocytes and
data from ‘The Human Protein Atlas’ suggest that EMR3 is not or only very lowly expressed in
colonic tissue.[21,22] EMR3 has been suggested to function as a mediator of invasive pheno-
typic variation in glioblastoma.[23]
Fig 1. Study design, variant filtering and candidate gene prioritization.Whole-exome sequencing was
performed on germline DNA of 55 early-onset CRC cases. The exome data were first filtered for quality and
frequency, followed by filtering for protein truncating and highly conserved missense variants. Next, we
removed all known loss-of-function-tolerant genes from this list and searched for known and novel CRC
predisposing gene variants.[12,13,57] An additional filtering was applied to identify genes that were affected
by two or more potentially pathogenic variants and to remove genes that are frequently affected by protein-
truncating or highly conserved missense variants in healthy controls. The remaining set of recurrent variants
was filtered for (i) genes recurrently affected by protein truncating variants; (ii) cancer driver genes in CRC
[23]; (iii) genes identified as CRC susceptibility genes in mice [29,30] and involved in cancer-related KEGG
pathways [hsa04310 (WNT signaling), hsa04350 (TGF-beta signaling), hsa03430 (mismatch repair),
hsa03410 (base excision repair), hsa03420 (nucleotide excision repair), map03450 (non-homologous end-
joining), hsa03460 (Fanconi anemia), and hsa05200 (pathways in cancer)] (iv) genes identified in CRC
GWAS studies [5–7,32]. Genes that remained after these filter steps were selected for re-sequencing in a
replication cohort of 174 CRC cases. CRC: colorectal cancer; VUS: variant of unknown significance.
doi:10.1371/journal.pgen.1005880.g001
Novel CRC Susceptibility Genes
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Second, we selected variants in genes that were identified as potential CRC driver genes (S8
Table).[24] We identified 16 variants in three genes:MSH6 (3 variants), TTN (10 variants) and
PTPN12 (3 variants). The tumors of the carriers of theMSH6 variants do not reveal MMR defi-
ciency and TTN is known to harbor an excess of rare private variants, is mainly expressed in
cardiac and skeletal muscle, and is associated with cardiomyopathies (MIM: 188840). There-
fore, we investigated the three rare variants in PTPN12 in more detail (Table 2). PTPN12
encodes the protein tyrosine phosphatase PTP-PEST that functions as a suppressor of epithe-
lial cell motility in CRC cells and has been linked to breast cancer development.[25–27] The
identified variants p.S684L (2 cases, subjects P045 and P054) and p.R522K (1 case, subject
P014) were found to be located adjacent to the proline-rich regions of PTP-PEST (Fig 2),
which have been shown to interfere with the kinase activity of PTP-PEST.[25–28] A data
search in ‘The Human Protein Atlas’ revealed that PTPN12 is expressed at high levels in
colonic tissue.[22] Somatic mutations that have been reported in PTPN12 were found to result
in truncations of the protein or in amino acid substitutions (Fig 2A).[24]
Third, we filtered for variants in genes that were identified as mouse CRC susceptibility
genes in transposon-based studies [29,30]. We identified 18 variants in eight such genes (S9
Table). Since most of these genes did not exhibit a clear link to cancer development, we filtered
our list for genes for those that are described in KEGG pathways implicated in CRC develop-
ment. This resulted in one remaining candidate, namely LRP6. In three CRC patients diag-
nosed before the age of 30 highly conserved LRP6missense variants with a predicted
pathogenicity, p.W239L (subject P002), p.N789S (subject P001) and p.T867A (subject P008),
were identified (Table 2). LRP6 encodes a receptor of the WNT-FZD-LRP5-LRP6 complex
that triggers β-catenin signaling. The LRP6 protein consists of four β-propeller domains, a
transmembrane domain, and a cytoplasmic domain. All variants were located in β-propeller
domains (Fig 3A and 3B), which are involved in the binding of WNT ligands and antagonists,
such as WNT3a and Dickkopf-1, respectively.[31] Data from ‘The Human Protein Atlas’
revealed that LRP6 is expressed at high levels in colonic tissue.[22] Interestingly, LRP6 has also
been found to be affected by somatic mutations in colorectal adenocarcinomas,[24] in which
most of these mutations appear to occur within in the β-propeller domains (Fig 3A), thus sup-
porting a role of missense variants in this gene in CRC development.
Fourth, we examined whether any of the genes that were previously identified in familial
CRC genome-wide association studies (GWAS)[32] were present in our list of genes recur-
rently affected by rare variants, but none were identified.
Frequency of identified variants in control populations
We analyzed the frequency of the potentially pathogenic variants that we identified in the
EMR3, PTPN12 and LRP6 genes in an additional cohort of locally sequenced control individu-
als without any suspicion for hereditary cancer, and in data from the Exome Aggregation Con-
sortium.[33] The local control individuals were sequenced at a high coverage and exhibited
sufficient read depth for our three candidate genes (Control dataset 2; n = 2,329; S2 Fig and
Materials and Methods for a detailed description). All variants that we identified in EMR3,
PTPN12 and LRP6 were either absent or present at an extremely low frequency in both these
data sets (MAF of0.001; Table 1). Next, we determined the number of variants in these three
genes with a similar predicted effect in ‘Control dataset 2’. This analysis revealed that protein-
truncating variants in EMR3 and missense variants with a PhyloP3.0 in PTPN12 and LRP6
are indeed enriched in our cohort of CRC patients, which remained significant after correcting
for multiple testing for three genes. After correcting for exome-wide multiple testing, none of
the genes were significantly enriched (S10 Table).
Novel CRC Susceptibility Genes
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Fig 2. Rare variants in PTPN12 encoding PTP-PEST in four cases. (A) Distribution of missense variants identified in the CRC discovery cohort (red dots)
and CRC replication cohort (blue dots) in PTP-PEST. Somatic PTPN12mutations identified in colorectal tumors [24] are indicated with black (missense) and
green (protein truncating) dots. The kinase domain is shown in yellow and the proline-rich-regions are shown in orange. (B) Amino acid conservation of the
three regions with missense variants (indicated with the red box) among 11 species, and the 3D protein structure of the kinase domain with the p.A105V
variant. The close up shows the structural difference between the mutant (red) and wild-type (green) residue. The mutant residue at position 105 is bigger
and may cause bumps during protein folding. The mutant residue at position 522 is smaller, which can result in loss of interactions. The mutant residue at
position 684 is more hydrophobic than the wild-type residue, this may disturb correct protein folding.
doi:10.1371/journal.pgen.1005880.g002
Novel CRC Susceptibility Genes
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Resequencing of novel candidate CRC susceptibility genes
Next, we performed targeted resequencing of the novel candidate CRC susceptibility genes
EMR3, PTPN12 and LRP6 using an Ion Ampliseq custom panel (Life technologies, see Materi-
als and Methods for details) and a replication cohort of 174 CRC cases (Table 1). With an aver-
age read-depth of 530-fold per targeted region [range: 21–1,852] per sample, one additional
rare potentially damaging variant in the kinase domain of the PTPN12 protein was identified
(p.A105V, subject RC204, age 45 years) and confirmed by Sanger sequencing (Table 2 and Fig
2). This is not a significant increase compared to ‘Control dataset 2’ (S10 Table). No additional
variants in EMR3 and LRP6 were identified.
Missense variants in LRP6 activate WNT signaling pathway
The three LRP6 variants identified were all encountered in individuals with a very early-onset
of the disease: 23, 24 and 29 years of age. To assess whether these LRP6 variants may have an
effect on the WNT signaling pathway, we performed TOPflash assays with LRP6 wild-type
(WT) and mutant proteins. Immunofluoresence andWestern blot analyses revealed similar
localization patterns and equal expression levels of the WT and mutant LRP6 proteins (Fig 3C
and 3D). Overexpression of the mutant LRP6 proteins (p.N789S and p.T867A) induced
1.6-fold (P = 0.0003) and 2.4-fold (P<0.0001) increases in WNT signaling activity in the TOP-
flash assay compared to the LRP6 WT protein, respectively (Fig 3E).
Cosegregation analysis
Based on the availability of suitable material, a cosegregation analysis could only be performed
for subject P002 (p.W239L; age 23 years). P002 did not have a clear family history of CRC, but
her mother, two sisters and an aunt developed breast cancer. We found that the mother also
carried the p.W239L variant. As we were unable to perform a complete cosegregation analysis
in this family, or in any of the other PTPN12 or LRP6 families, it remains to be established to
what extend carriers of variants in these genes tend to develop cancer at a young age.
Discussion
In this study we have performed whole-exome sequencing on germline DNA from 55 mis-
match repair-proficient early-onset CRC cases and identified multiple potentially damaging
variants in two colon-expressed genes: PTPN12 and LRP6. The germline variants identified in
these genes appeared to affect highly conserved amino acids and were absent, or present at
extremely low frequencies, in control populations. Targeted re-sequencing of a replication
cohort of 174 individuals with early-onset CRC revealed one additional variant in PTPN12. We
also found that two of the three missense variants in LRP6 can activate the WNT pathway in
Fig 3. Rare variants in LRP6 in three cases. (A) Distribution of missense LRP6 variants identified in the CRC discovery cohort (red dots). Somatic LRP6
mutations identified in colorectal tumors [24] are indicated with grey (missense) and black (protein truncating) dots. Structural domains include the β-propeller
domains that are used to form the receptor complex (pink bars), and the transmembrane domain (purple). (B) 3D protein structure of the β-propeller domains
of LRP6 with the positions of the identified missense variants in red. Insets show conservation of the region in which the missense variants (indicated with the
red box) are located with, underneath, close ups of the local 3D protein structure with mutant (red) and wild-type (green) residues. The mutant residue at
position 239 is predicted to disturb the protein structure (project HOPE; http://www.cmbi.ru.nl/hope/). The mutant residue at position 789 is much smaller than
the wild-type residue and may disturb the binding of Dickkopf-1. Residue 867 is located on the surface of the protein and the mutant residues are not
expected to disturb protein structure, but may influence protein binding. (C) Immunofluorescence analyses of LRP6 wild-type and mutant proteins showing
similar subcellular localizations. (D) LRP6 protein expression levels normalized to β-actin are similar between wild-type and mutant LRP6. (E) TOPflash
analyses of wild-type and mutant LRP6 to determine their effects on theWNT signaling pathway. Luciferase activity was normalized to control and wild-type
constructs. Both p.N789S and p.T867Amutants reveal a significant increase in activation compared to the wild-type LRP6 protein. Experiments were
performed three times in triplicate. **P <0.001; error bars represent the standard error of the mean.
doi:10.1371/journal.pgen.1005880.g003
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vitro. Based on these results, we propose that PTPN12 and LRP6 serve as novel moderately pen-
etrant CRC susceptibility genes.
Within our discovery cohort, we focused on genes that were recurrently affected by rare
potentially damaging variants. Rare variants represent the vast majority of normal variation in
the human genome and they are unequally distributed between genes and between biological
pathways,[34–37] illustrating that a comparison with exome sequence data from a geographi-
cally matched control cohort is crucial. We, therefore, selected only variants with a MAF
0.001 in locally sequenced control individuals, and applied the entire analysis pipeline to a
dataset of 164 healthy controls that were sequenced using the same exome enrichment and
sequencing procedures. This approach allowed us to reduce the risk of selecting locally com-
mon benign variants, to prevent the selection of false-positives by technical errors, and to focus
only on genes that are protected from gathering pathogenic mutations in the normal popula-
tion.[38] Furthermore, we analyzed an additional, more recent, high quality exome sequencing
dataset from local individuals to confirm that our identified variants were indeed extremely
rare.
One of the candidate genes, PTPN12, encodes the widely expressed cytoplasmic protein
tyrosine phosphatase PTP-PEST, which regulates epithelial cell adhesion and migration.
[25,39–41] In colon carcinoma cells, PTP-PEST has been shown to control cell motility and
adherence junction assembly by regulating the intracellular localization of p120 catenin and,
consequently, its interaction with E-cadherin.[27] Therefore, PTP-PEST may play a role in the
tightly controlled migration of epithelial cells of the colonic crypts. The highly conserved vari-
ants identified in our study may result in diminished phosphatase activity, as has been demon-
strated for comparable missense variants in the same domains,[26,28] resulting in aberrant
crypt formation and possibly invasion.
LRP6 is a core-component of the WNT-FZD-LRP5-LRP6 receptor complex of the WNT
signaling cascade, which is commonly activated in colon cancer.[42] Previously, this gene was
also identified in a screen for mouse CRC susceptibility loci.[30] Remarkably, we found that
the rare LRP6 variants were present in three of the youngest diagnosed individuals in our
cohorts (age 23, 24 and 29). Furthermore, two of the identified missense variants in LRP6 were
found to be located at positions of the protein that interact with the WNT antagonist Dick-
kopf-1 [43] and to result in significantly increased activations of the WNT pathway in in vitro
TOPflash reporter assays. This finding is intriguing, as it was recently shown that missense var-
iants in LRP6 can abrogate activation of the WNT pathway.[44]
Despite the fact that EMR3 is recurrently affected by rare protein truncating variants in our
discovery cohort, we do not consider EMR3 a strong candidate gene for CRC susceptibility,
since the protein is not or only very lowly expressed in tissue from colon and rectum, and we
could not establish a functional link to CRC development.[21–23]
Several recent whole-exome sequencing studies have revealed novel candidate CRC suscep-
tibility genes and variants,[45–51] but the concordance between these findings, including our
own, is as yet limited, and statistical evidence for these correlations in case-control studies was
not obtained. This limited concordance may be due to different patient inclusion criteria used,
ranging from the selection of predominantly familial cases to individuals with isolated CRC at
young age. In addition, it cannot be excluded that non-genetic (environmental) risk factors
may have played a role in the development of CRC at a younger age in individual cases. Clearly,
the genetic heterogeneity of CRC susceptibility may also, at least partly, explain the limited
concordance between studies, and points out that statistical validation required very large case
and control cohorts. Optimal phenotypic pre-selection, including genetic or histologic abnor-
malities in the tumor, or even the presence of additional congenital features as we recently
identified in individuals with BUB1 and BUB3 abnormalities,[52] may limit this heterogeneity.
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Furthermore, variant selection varies between studies. So far, most studies have put a primary
focus on high-penetrance germline mutations by showing cosegregation within families and
second-hit mutations in the tumor,[45–50] but this approach may not be valid for predisposing
variants with a moderate penetrance.
The inclusion of missense variants as potential candidates is challenging, because their effect
is difficult to predict, and can vary widely between variants in a particular gene. Nevertheless,
the putative relevance of missense variants in functionally important domains should not be
underestimated, as was recently illustrated by the discovery of missense POLE and POLD1 vari-
ants.[4] Functionally important domains are conserved both at the nucleic acid and the amino
acid level. Currently, there is no consensus on the best strategy to discriminate pathogenic mis-
sense variants from benign missense variants, which poses a challenge to this type of cohort
studies. We have used PhyloP scores as the first prioritization cut-off in the pathogenicity
assessments, as it was previously shown that pathogenic variants have higher scores than
benign variants,[53] This prioritization step was followed by other in silico steps to predict
pathogenicity based on the biophysical amino acid characteristics and multiple protein
sequence alignments. Finally, essential evidence for the role of damaging variants in novel
genes may results from the presence of these variants in independent families, but their fre-
quency is expected to be low. Therefore, large replication series are needed that encompass
comparable cases to replicate the findings. Additionally, more and better candidates are likely
to be identified when datasets from different studies are merged and re-analyzed. We did, how-
ever, identify several rare variants in single individuals in candidate CRC susceptibility genes
previously reported by others (S11 Table). The same may, in reverse, turn out to be true for
PTPN12 and LRP6.
In conclusion, we and others have shown by whole-exome sequencing that the genetic sus-
ceptibility to CRC is heterogeneous. Our findings are in line with a polygenic model of CRC
susceptibility in which multiple risk factors in known and novel CRC pathways may contribute
to additive risks.[54] Future studies, such as functional assessments of the candidate genes and
replications in larger CRC and control cohorts, are needed to firmly establish the role of
PTPN12 and LRP6 in CRC susceptibility.
Materials and Methods
Study samples
The discovery cohort used consists of 55 non-polyposis DNAmismatch repair (MMR)-profi-
cient CRC cases, diagnosed at45 years of age, which were referred to the Radboud university
medical center, Nijmegen, the Netherlands (Table 1 and S1 Table).[12,52] The replication
cohort used consists of 174 MMR-proficient CRC cases from both Nijmegen, The Netherlands,
and Dresden, Germany, that fulfilled one of the following two criteria: (i) diagnosed with CRC
40 years of age (n = 90) regardless of family history, or (ii) diagnosed with CRC50 years of
age with at least two first-degree relatives with CRC (n = 84). All individuals provided written
informed consent. The study was approved by the CMO (study number 2009/256), Arnhem
and Nijmegen, the Netherlands.
Whole-exome sequencing
Whole-exome sequencing was performed on genomic DNA extracted from peripheral blood
cells of cases included in the CRC discovery cohort with SOLiD4 (n = 10) and 5500xl (n = 45)
sequencing platforms (Life technologies, Carlsbad, CA, USA) using the SOLiD-optimized Sur-
eSelect Human All Exon kit V1 (30Mb set, n = 1), V2 (50Mb set, n = 44) and V4 (50Mb set,
n = 10; Agilent Technologies, Santa Clara, CA, USA) as described previously.[12,52,55]
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Sequencing reads were mapped to the hg19 reference genome using SOLiD LifeScope V2.1
software (Life technologies, Carlsbad, CA, USA).
Prioritization of variants
Variants were annotated using an in-house annotation pipeline, as described previously.
[12,52,55] High-confidence calls (i.e.10 reads,5 variant reads,5 unique starts (available
only for substitutions) and28% variant reads) were filtered for non-synonymous variants
that were absent in our in-house variant database. This in-house variant database consists of
variants identified by exome sequencing in 2,037 individuals from mostly Western European
Ancestry (>95%) that were sequenced using SureSelect Human All Exon kit V2 and SOLiD4
sequencers (~64% of exomes), Exon kit V4 and 5500xl sequencers (~25% of exomes), or Exon
kit V4 and Illumina HiSeq 2500 sequencers (~11% of exomes). All SOLiD4 and 5500xl exomes
were mapped and called with LifeScope V2.1 software and the Illumina exomes were mapped
with BWA and called using GATK. All exomes were sequenced at a median coverage of at least
50-fold. Next, we removed all variants present with a MAF of>0.001 in The National Heart,
Lung, and Blood Institute Exome Sequencing Project database (6,503 exomes),[11] and genes
that were described to be loss-of-function tolerant.[56]
Subsequently, variants that resulted in protein truncations (i.e. putative frameshifts, non-
sense mutations and variants at canonical splice-sites), and non-synonymous variants with a
PhyloP score3.0 (missense mutations) were selected (S3 Table). The remaining list was ana-
lyzed for variants in known CRC predisposing genes and genes that predispose to other types
of cancer and/or cause recessive cancer syndromes.[12,13,57]
In the next filter step, all recurrent variants and genes recurrently affected were selected.
This list of variants was subsequently filtered based on the occurrence of rare potentially patho-
genic variants in a whole-exome sequence data set of 164 anonymous healthy controls (Control
dataset 1) that were extracted from a study reported by de Ligt et al.[55] These exomes were
sequenced using a SureSelect Human All Exon kit V2 and SOLiD4 sequencers, mapped and
called using SOLiD LifeScope V2.1 software, after which a filtering appoach identical to the
one described for our CRC discovery cohort was applied. Analysis by a genotype-weighted
metric described by Heinrich et al. [58] revealed that the exomes of the CRC patients and those
from ‘Control dataset 1’ were comparable, both in terms of genetic origin and sequencing per-
formance (S1 Fig). Significance of differences between the frequencies of variants in our CRC
discovery cohort and this dataset of 164 controls were calculated using the χ2 goodness of fit
test and a Benjamini-Hochberg (BH) correction for multiple testing was performed (corrected
for 196 genes that harbored recurrent variants or were recurrently affected in our CRC discov-
ery cohort). A P-value of0.05 was considered significant before correction. After correction a
χ2 P-value less than the BH critical value was considered significant. None of the genes were
significantly enriched in our CRC discovery cohort after correcting for multiple testing. There-
fore, we continued with the genes that revealed a χ2 goodness of fit P-value of0.05 before
multiple testing. This remaining list of variants was subjected to the following prioritization
(Fig 1): (i) genes recurrently affected by protein-truncating variants solely; (ii) potential CRC
driver genes (S8 Table) [24]; (iii) genes identified in transposon-based CRC susceptibility stud-
ies in mice [29,30] and involved in CRC-related KEGG pathways [pathways hsa04310 (WNT
signaling), hsa04350 (TGF-beta signaling), hsa03430 (mismatch repair), hsa03410 (base exci-
sion repair), hsa03420 (nucleotide excision repair), map03450 (non-homologous end-joining),
hsa03460 (Fanconi anemia), and hsa05200 (pathways in cancer)] (S9 Table); and (iv) genes
identified through GWAS studies [5–7,32]. Prioritized variants were further analyzed in silico
using software packages Align-GVGD, SIFT and Polyphen-2 integrated in the Alamut 2.0
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software package (Interactive Biosoftware), and ‘HOPE’ (http://www.cmbi.ru.nl/hope) was
used to assess the structural effects of missense variants at the protein level.[59] All selected
variants were validated using Sanger sequencing.
Comparisons to control populations
To investigate whether the variants we identified were truly rare, we analyzed their frequency in
the dataset from the Exome Aggregation Consortium [33] and in an independent exome data set
from a cohort of individuals of mostly Western-European/Dutch ancestry (Control dataset 2; n =
2,329) from which paired-end exome sequencing data were available with an average>90-fold
coverage for our candidate genes (Agilent V4 kit; Illumina HiSeq 2500, S2 Fig). This cohort did
not contain any cases with a suspected hereditary form of cancer. In addition, we assessed the fre-
quency of potentially pathogenic variants with a MAF0.001 in our candidate genes in the latter
dataset. Comparisons between the Discovery cohort and ‘Control dataset 2’ were performed
using the Fisher’s exact test followed by a Benjamini-Hochberg correction for the three candidate
genes and for exome-wide multiple testing. A P-value of0.05 was considered significant.
Targeted re-sequencing
Amultiplex AmpliSeq panel (Ion AmpliSeq Designer, Life technologies) was designed, target-
ing all coding exons of EMR3, PTPN12 and LRP6. For library preparation, four DNA samples
from the replication cohort were equimolarly pooled and used for amplification. Libaries were
barcoded using Ion Xpress Barcode adapters, run on an OneTouch emulsion PCR system (Life
Technologies), and sequenced using three Ion 318 chips (Life Technologies). Variant calling
and annotation were performed using SeqNext (JSI Medical Systems, Kippenheim, Germany).
Variants with a MAF of0.001 in the EVS that resulted in protein truncations, splice-site
defects, or missense mutations with a PhyloP3.0 were selected and validated by Sanger
sequencing in the four samples of the subsequent pool. The frequencies of variants in this CRC
replication cohort and the ‘Control dataset 2’ were calculated using the Fisher’s exact test, and
a Benjamini-Hochberg correction for multiple testing was performed. A P-value of0.05 was
considered significant.
LRP6 localization and expression analyses
The human image clone IRCMp5012G1125D (Source BioScience, Nothingham, UK) was used
to amplify the full-length cDNA of LRP6. This cDNA was subcloned into a cTAP vector in
front of an in-frame C-terminal Flag-tag using the Gateway cloning system (Invitrogen, Carls-
bad, CA, USA). Mutations were introduced using site-directed mutagenesis, and the open read-
ing frames were confirmed by Sanger sequencing. For localization studies, CHO cells were
grown on microscope glass slides and transfected with the wild-type or mutant LRP6 con-
structs using an X-tremeGENE tranfection reagent (Invitrogen). After 48 hrs, cells were fixed,
incubated with a rabbit polyclonal anti-Flag antibody (Sigma Aldrich, St. Louis, USA), embed-
ded in Vectashield with DAPI, and analyzed by fluorescence microscopy. Expression of wild-
type or mutant LRP6 was compared by Western blot analyses using a rabbit polyclonal anti-
Flag antibody and a goat polyclonal anti-actin antibody (Santa Cruz) and visualized using an
Odyssey infrared system (Li-cor Biosciences, NE, USA).
TOPflash reporter assay
CHO cells were transfected in 96-well plates with wild-type or mutant LRP6 constructs
together with TOP- or FOPflash reporter constructs (plasmid 12456 and 12457; Addgene,
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Cambridge, MA, USA) using an X-tremeGENE transfection reagent (Invitrogen).[60] The cul-
ture medium was refreshed 24 hrs post-transfection with normal or WNT3a-conditioned
medium, and luciferase activity was measured after 16 hrs using a Dual-Glo Luciferase kit (Pro-
mega) and an InfiniteM200-Pro plate reader (Tecan). The expression of the reporter was nor-
malized to co-transfected Renilla luciferase. Differences between wild-type or mutant LRP6
were assessed using a student’s t-test. A P-value of0.05 was considered significant.
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